Vermillion Announces Date Change for Fourth Quarter and Full Year 2015 Financial Results

AUSTIN, Texas, March 21, 2016 /PRNewswire/ -- Vermillion, Inc. VRML, a bio-analytical solutions company focused on gynecologic disease, announced today it will report its fourth quarter and full year 2015 financial results on Thursday, March 24, 2016, followed by an investor conference call and webcast at 8:30am Eastern.

About Vermillion
Vermillion, Inc. is dedicated to the discovery, development and commercialization of novel high-value diagnostic and bio-analytical solutions that help physicians diagnose, treat and improve gynecologic health outcomes for women.  Vermillion, along with its prestigious scientific collaborators, discovers, develops, and delivers innovative diagnostic and technology tools that help women conquer over serious diseases.  The company's lead diagnostics in the United States, OVA1®, and Overa®, are blood tests for pre-surgical assessment of ovarian tumors for malignancy, each using an innovative algorithmic approach. Overa and OVA1, which was the first FDA-cleared, protein-based In Vitro Diagnostic Multivariate Index Assay, represent a new class of software-based diagnostics. For additional information, including published clinical trials, visit www.vermillion.com.  

Investor Relations Contact:
Michael Wood
LifeSci Advisors LLC
Tel 1-646-597-6983
mwood@lifesciadvisors.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/vermillion-announces-date-change-for-fourth-quarter-and-full-year-2015-financial-results-300238647.html

SOURCE Vermillion, Inc.